Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8708196 | 0.98 | HDAC3 (0.54) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8993155 | 0.98 | HDAC3 (0.54) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1983580 | 0.98 | HDAC3 (0.54) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL17508108 | 0.96 | MAOA (0.54) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL17527074 | 0.94 | MAOA (0.52) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3666097 | 0.94 | MAOA (0.52) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16390835 | 0.94 | MAOA (0.52) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL17527067 | 0.94 | MAOA (0.52) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1685452 | 0.94 | CARM1 (0.53) | MAOAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8027241 | 0.90 | HDAC3 (0.50) | MAOAHDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0407032-B1 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | WYETH JOHN & BROTHER LTD (GB) | 1994-11-09 | — | — | EP | claimed |
| US-5086073-A | Brain disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1992-02-04 | — | — | US | claimed |
| EP-0407032-A2 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-09 | — | — | EP | claimed |
| CN-111989316-B | Process for the production of (6S, 15S) -3,8,13,18-tetraazaeicosane-6, 15-diol | 潘贝拉治疗股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-111989316-A | Process for the production of (6S,15S) -3,8,13, 18-tetraazaeicosane-6, 15-diol | 太阳生物制药股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-1296931-B1 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | MEDIQUEST THERAPEUTICS INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1159261-B1 | ANTIZYME MODULATORS AND THEIR USE | ORIDIGM CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6872852-B2 | Polyamine analogues as cytotoxic agents | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| CN-1426391-A | Polyamine analogues as cytotoxic agents | ORIDIGM CORP (US) | 2003-06-25 | — | — | CN | disclosed |
| EP-1296931-A2 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | MediQuest Therapeutics, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030045755-A1 | Polyamine analogues as cytotoxic agents | MEDIQUEST THERAPEUTICS, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2001072685-A9 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | ORIDIGM CORP (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1159261-A2 | ANTIZYME MODULATORS AND THEIR USE | ORIDIGM CORPORATION (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001072685-A2 | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | ORIDIGM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000046187-A2 | ANTIZYME MODULATORS AND THEIR USE | ORIDIGM CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
| US-5677350-A | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1996040096-A1 | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0407032-A2 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-09 | — | — | EP | disclosed |